Şunu aradınız:: amoxicillin (İngilizce - Maltaca)

amoxicillin
amoxicillin

amoxicillin amoxicillin
amoxicillin amoxicillin

micronised amoxicillin (as trihydrate)
amoksiċillina mikronizzat (bħala tri- idrat)

ciprofloxacin and amoxicillin plus clavulanic acid
ciprofloxacin u amoxicillin flimkien ma’ clavulanic acid

suramox 15% la, suspension for injection amoxicillin
suramox 15% la, suspensjoni għal injezzjoni amoksiċillina

do not use in case of known resistance to amoxicillin
tużax f’ każijiet ta ’ reżistenza magħrufa għall- amoksiċillina.

micronised amoxicillin (as trihydrate) 150.0 mg/ ml
amoksiċillina mikronizzat (bħala tri- idrat)

15 mg amoxicillin/ kg bw (equivalent to 1ml/ 10 kg)
15 mg amoxicillin/ kg

micronised amoxicillin (as trihydrate) 150.0 mg/ ml excipient:
amoksiċillina mikronizzat (bħala tri- idrat) 150. 0 mg sustanza mhux attiva:

investigated medicinal products with no clinically relevant interaction amoxicillin and quinidine
prodotti mediċinali investigati bl-ebda interazzjoni klinikament rilevanti amoxicillin u quinidine

after intramuscular administration amoxicillin is well absorbed and distributed in the tissues.
wara li l- amministrazzjoni intramuskolari l- amoksiċillina tiġi assorbita sew u mqassma ġot- tessut.

inappropriate use of the product may increase the prevalence of bacteria resistant to amoxicillin.
l - użu mhux addattat tal- prodott jista ’ jżid il- prevalenza ta ’ batterji reżistenti għall- amoksiċillina.

amoxicillin is susceptible to breakdown by ß-lactamases produced by some bacterial strains.
amoksiċillina hu suxxettibbli li jinqasam minn ß- lactamasi li huma prodotti minn xi tensjonijiet batterjali.

esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin and quinidine.
esomeprazole intwera li ma għandu l-ebda effett klinikament rilevanti fuq il-farmakokinetika ta’ amoxicillin u quinidine.

of residues of amoxicillin when administered by injection it was not possible to establish a withdrawal period for cattle and pigs as:
- is- cvmp ikkonsidra li skond id- data ta ’ l- eliminazzjoni tar- residwi pprovduta dwar l- eliminazzjoni

oseltamivir has no kinetic interaction with amoxicillin, which is eliminated via the same pathway, suggesting that oseltamivir interaction with this pathway is weak.
dan jissuġerixxi li l- interazzjoni ta 'oseltamivir ma' dan il- passaġġ hi dgħajfa.

a further three trials looked at its effects in treating pyoderma: two compared it with enrofloxacin and one compared it with amoxicillin and clavulanic acid.
tliet provi oħra ħarsu lejn l-effetti tiegħu fit-trattament tal-pyoderma: tnejn qabbluh ma’ enrofloxacin u waħda qabblitu ma’ amoxicillin u clavulanic acid.

two of these studies compared dicural with enrofloxacin and one compared it with the combination of amoxicillin and clavulanic acid (used together as an antibiotic).
tnejn minn dawn il-provi qabblu dicural ma’ enrofloxacin u waħda qabblitu ma’ kombinazzjoni ta’ amoxicillin u clavulanic acid (użati flimkien bħala antibijotiku).

where antibiotics must be used, preference should be given to agents with no anti-mycoplasma activity, such as penicillin, amoxicillin or neomycin.
fejn ikun hemm bżonn li jintużaw l-antibijotiċi, għandha tingħata preferenza lill-aġenti mingħajr ebda attività anti-mikoplażma, bħal peniċillina, amoxicillin jew neomycin.

all samples were analysed for amoxicillin concentrations using a validated hplc-ms/ ms method with a limit of quantification of 25 µg/ kg for all tissues.
il- kampjuni kollha ġew analizzati għall- konċentrazzjoni ta ’ amoxicillin bl- użu ta ’ metodu ta ’ hplc- ms/ ms validat b’ limitu ta ’ kwantifikazzjoni ta ’ 25 µg/ kg għat- tessuti kollha.